L&K Biomed Ltd. (KOSDAQ:156100)
South Korea · Delayed Price · Currency is KRW 3,985.00
-5.00 (-0.13%)
At close: Jul 28, 2026
L&K Biomed Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 89,069 | 272,576 | 132,181 | 202,956 | 107,379 | 143,972 | |
Market Cap Growth | -39.05% | 106.21% | -34.87% | 89.01% | -25.42% | -71.54% |
Enterprise Value | 82,506 | 278,305 | 129,243 | 200,512 | 115,624 | 150,234 |
Last Close Price | 3985.00 | 12960.00 | 6630.00 | 10180.00 | 7212.36 | 9679.51 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 13.57 | - | - | - |
Forward PE | - | 19.67 | 19.67 | 26.72 | 25.02 | 25.02 |
PS Ratio | 2.25 | 7.00 | 3.66 | 6.79 | 5.43 | 9.37 |
PB Ratio | 1.72 | 7.06 | 3.67 | 6.64 | 9.98 | 5.81 |
P/TBV Ratio | 1.53 | 6.14 | 3.19 | 5.87 | 9.29 | 6.19 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.09 | 7.15 | 3.58 | 6.71 | 5.85 | 9.77 |
EV/EBITDA Ratio | 24.56 | 79.58 | 22.88 | 46.12 | - | - |
EV/EBIT Ratio | 140.91 | 389.17 | 41.99 | 98.58 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.53 | 0.50 | 0.65 | 0.44 | 2.34 | 0.91 |
Debt / EBITDA Ratio | 7.73 | 5.47 | 4.14 | 3.11 | - | - |
Net Debt / Equity Ratio | 0.02 | 0.33 | 0.10 | 0.02 | 1.13 | 0.13 |
Net Debt / EBITDA Ratio | 0.26 | 3.68 | 0.61 | 0.17 | -1.17 | -0.24 |
Net Debt / FCF Ratio | -0.06 | -0.76 | -0.43 | -0.22 | -1.82 | -0.31 |
Asset Turnover | 0.40 | 0.47 | 0.50 | 0.52 | 0.35 | 0.26 |
Inventory Turnover | 0.20 | 0.23 | 0.27 | 0.24 | 0.33 | 0.48 |
Quick Ratio | 0.89 | 0.65 | 0.90 | 1.04 | 0.50 | 1.70 |
Current Ratio | 1.64 | 1.60 | 1.63 | 1.95 | 0.95 | 3.01 |
Return on Equity (ROE) | -18.25% | -44.98% | 27.47% | -25.34% | -91.33% | -46.30% |
Return on Assets (ROA) | 0.50% | 0.54% | 2.64% | 2.20% | -14.22% | -16.15% |
Return on Invested Capital (ROIC) | 1.51% | 1.57% | 8.11% | 7.49% | -49.97% | -41.32% |
Return on Capital Employed (ROCE) | 1.30% | 1.60% | 7.00% | 5.10% | -86.80% | -32.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -8.27% | -5.98% | 7.37% | -0.92% | -12.69% | -6.72% |
FCF Yield | -17.98% | -6.19% | -6.06% | -1.68% | -6.22% | -7.29% |
Buyback Yield / Dilution | 4.40% | 6.53% | -34.13% | -21.04% | -0.07% | -12.57% |